Drug Trial Radar · NCT00000556
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
Last checked: Nov 19, 2026Latest source record: Mar 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
Not stated
Start
Mar 1995
Primary completion
Not stated
Study completion Sep 2002
Sponsor
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)NIH
- Sponsor type
- NIH
- First posted
- Oct 28, 1999
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 65 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.
Conditions
- Arrhythmia
- Atrial Fibrillation
- Cardiovascular Diseases
- Heart Diseases
Interventions
amiodaroneDrug
sotalolDrug
propafenoneDrug
flecainideDrug
quinidineDrug
moricizineDrug
disopyramideDrug
procainamideDrug
adrenergic beta antagonistsDrug
verapamilDrug
diltiazemDrug
digoxinDrug
catheter ablationProcedure
pacemaker, artificialDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.